Parker Institute for Cancer Immunotherapy Showcases Research at ASCO 2026
The Parker Institute for Cancer Immunotherapy (PICI) is set to have a significant presence at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026. PICI will contribute to over 50 oral sessions, posters, and publications, highlighting its extensive work in cancer immunotherapy. The institute's research spans various cancers, including glioblastoma, melanoma, prostate, breast, lung, and urothelial cancers. Notably, PICI will present new data from its RADIOHEAD pan-cancer cohort, focusing on multimodal immunoprofiling to predict immunotherapy responses and toxicity. Additionally, PICI will announce the first recipient of the Conquer Cancer PICI Endowed Young Investigator Award, recognizing an outstanding early-career clinical oncology investigator. 
